HTMC0435

HTMC0435 is an investigational small molecule drug that acts as a poly (ADP-ribose) polymerase (PARP) inhibitor, specifically targeting PARP1 and PARP2. It is being developed for the treatment of various advanced solid tumors, with a primary focus on recurrent extensive stage small cell lung cancer (SCLC). The drug is administered orally and has reached Phase 2 clinical trials in China for indications including biliary tract cancer, neuroendocrine tumor of the pancreas, advanced malignant solid neoplasms, and SCLC. Its mechanism involves inhibiting DNA repair in cancer cells by blocking PARP enzymes, thereby promoting cell death in tumor cells reliant on these pathways for survival. The developers are Shanghai Huilun Life Science and Technology Co., Ltd. and Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.[1][2][3][7]

Other names

HTMC0435HTMC-0435HTMC 0435